Navigation Links
Micromet and MedImmune Present Data From Preclinical Study of New,BiTE Molecule Targeting CEA

egulatory approval or that, even if regulatory approval is received, any such product will be commercially successful. MedImmune undertakes no obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise except as may be required by applicable law or regulation.

Forward-Looking Statements of Micromet, Inc.

This release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include statements regarding the intended utilization of product candidates, the conduct and results of future clinical trials, plans regarding regulatory filings, future research, discovery of new product candidates, and clinical trials, and partnering activities. Factors that may cause actual results to differ materially include the risk that product candidates that appeared promising in early research and clinical trials do not demonstrate safety and/or efficacy in larger-scale or later clinical trials, the risks associated with regulatory processes, the risks associated with reliance on outside financing to meet capital requirements, and the risks associated with reliance on collaborative partners for future revenues under the terms of its existing collaboration agreements, and for further pre-clinical and clinical studies, development and commercialization of product candidates. You are urged to consider statements that include the words "appear," "may," "will," "would," "could," "should," "believes," "estimates," "projects," "potential," "expects," "plans," "anticipates," "intends," "continues," "forecast," "designed," "goal," or the negative of those words or other comparable words to be uncertain and forward-looking. These factors and others are more fully discussed in Micromet's periodic reports a
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Micromet, Inc. to Present at the 3rd Annual C.E. Unterberg, Towbin Emerging Growth Conference
2. Publication Confirms that EpCAM, the Target for Two of Micromets Product Candidates, Is Overexpressed on Cancer Stem Cells of Certain Cancers
3. Micromet Achieves Milestone in BiTE Research Collaboration with MedImmune
4. MedImmune and Micromet Publish Data on Novel Anti-Cancer BiTE Molecule
5. Infinity and MedImmune Present Updated Phase I Results of IPI-504 in GIST at ASCO Annual Meeting
6. Infinity and MedImmune Announce Updated Data On Ipi-504 to be Presented At ASCO
7. MedImmune Highlights Advances in Inflammatory Disease Pipeline With Series of Data Presentations
8. MedImmune Announces Positive Clinical Results at PAS Annual Meeting From Large Prospective Trial in Prevention of Serious RSV Disease
9. Pediatric Academic Societies Annual Meeting to Feature Data Presentations Related to MedImmune Clinical Programs in Influenza, RSV and hMPV
10. MedImmune Publishes New Data in Nature Immunology Demonstrating The Role HMGB1 May Play in Systemic Autoimmune Diseases
11. Infinity and MedImmune to Present Preclinical Data From Study of Oral Formulation of IPI-504 At AACR
Post Your Comments:
(Date:5/22/2013)... May 22, 2013 Ranbaxy Laboratories Limited ... Ltd. (hereafter, Daiichi Sankyo), announced on May 22 ... years to address past conduct under prior management ... Daiichi Sankyo continues to support Ranbaxy in ... of the past which led to the investigations ...
(Date:5/22/2013)...  Grifols, ein globales Unternehmen der Gesundheitsbranche ... , Spanien, präsentierte die Ergebnisse einer Studie, ... PROLASTIN©-C (Alpha1-Proteinasehemmer [human]) den Spiegel des Alpha1-Proteins ... Niveau anhebt, das innerhalb des für gesunde ... eine lebensbedrohliche, genetische Erkrankung, bei der der ...
(Date:5/22/2013)... Israel , May 22, 2013 /PRNewswire/ ... leading developer and provider of microRNA-based molecular diagnostics, announces ... and Chief Executive Officer of Rosetta Genomics, will deliver ... taking place from June 3-6, 2013 in New York ... June 4 th at 2:00 p.m. Eastern time. ...
Breaking Medicine Technology:Studie von Grifols zeigt, dass eine höhere Dosis von PROLASTIN-C den Alpha1-PI-Spiegel in Patienten mit AAT-Mangel in den normalen Bereich anhebt 2Studie von Grifols zeigt, dass eine höhere Dosis von PROLASTIN-C den Alpha1-PI-Spiegel in Patienten mit AAT-Mangel in den normalen Bereich anhebt 3Studie von Grifols zeigt, dass eine höhere Dosis von PROLASTIN-C den Alpha1-PI-Spiegel in Patienten mit AAT-Mangel in den normalen Bereich anhebt 4Rosetta Genomics to Present at the Jefferies 2013 Healthcare Conference 2Rosetta Genomics to Present at the Jefferies 2013 Healthcare Conference 3
(Date:5/22/2013)... 22, 2013 According to a May 14, ... More Options for Breast Cancer Surgery,” modern medical technology has ... approach this disease in a whole new light. Since the ... now face breast cancer and mastectomies with greater ... “Before the introduction of plastic surgery to oncology, women had ...
(Date:5/22/2013)... next two decades, the cost of treating strokes in ... topping more than $180 billion a year, according to ... an aging population. The report, from the American Heart ... May 22 in the journal Stroke . ... Bruce Ovbiagele, chairman of the department of neurology at ...
(Date:5/22/2013)... 22, 2013 Recent tragedies including ... the school shooting in Newtown, Connecticut all resulted ... , Emergency medical practitioners train to respond ... Emergency Medical Services for Children (EMSC) Program specifically ... for the youngest patients. It is estimated 30 ...
(Date:5/22/2013)... (PRWEB) May 22, 2013 HR Strategies ... hosted at the Gwinnett County Fairgrounds, on Friday May ... before, they far surpassed expectations; raising over $6,300 for ... sponsor for the event, donating the first $3,000 for ... , challenged the internal staff to match the company’s ...
(Date:5/22/2013)... Alan Mozes HealthDay Reporter , , WEDNESDAY, May ... number of American children who die each year awaiting ... research reveals. And increasing numbers of children are receiving ... of potential organ donors expanded to include not just ... a "circulatory determination of death." But it,s unclear ...
Breaking Medicine News(10 mins):Health News:Breast Augmentation – New Option for Breast Cancer Surgeries 2Health News:Cost of Treating Strokes in U.S. Could Soar to $180B Annually by 2030: Report 2Health News:Cost of Treating Strokes in U.S. Could Soar to $180B Annually by 2030: Report 3Health News:When Tragedies Impact Children – Kentucky Emergency Medical Services for Children (KYEMSC) Offers Specialized Training for Pediatric Emergency Care 2Health News:HR Strategies Raises Over $6,300 for Cancer Research via Relay For Life 2Health News:More Kids Getting Donor Organs, But Gaps Persist, Study Finds 2Health News:More Kids Getting Donor Organs, But Gaps Persist, Study Finds 3Health News:More Kids Getting Donor Organs, But Gaps Persist, Study Finds 4
... SALT LAKE CITY, Jan. 5 Health-conscious consumers who ... day now have a smaller,more powerful alternative to fish ... MegaRed delivers essential omega-3 fatty acids combined with,powerful antioxidants, ... supporting,heart health. One MegaRed softgel per day -- which ...
... VIEW, Calif., Jan. 5 Based on its ... Sullivan recognizes Toshiba,America Medical Systems with the 2008 ... The company has launched a variety of,cardiovascular imaging ... cardiac ultrasound line. This product has taken,echocardiography a ...
... Treat Diseases (HTDS) www.htdsmedical.com Further to the ... company addressed several targeted merger candidates, the company is ... negotiations with Slavica Bio Chem, www.slavicabiochem.com (Slavica). ... Renuyu Biochem, a USA and a UK company, founded ...
... IRVING, Texas, Jan. 5 RBC Life Sciences ... has elected current president, John W. Price, to CEO ... is currently CEO, will remain as chairman of the ... RBC Life Sciences, a global provider of proprietary nutritional ...
... Licenses PDL,s Queen et al. Patents for Soliris(R) INCLINE VILLAGE, ... (Nasdaq: PDLI ) and Alexion Pharmaceuticals, Inc. ... the companies have entered into a definitive license agreement and ... to Alexion,s humanized antibody, Soliris(R) (eculizumab) and PDL,s patents known ...
... Jan. 5 The Ensign Group, Inc. (Nasdaq: ... has acquired Southland Healthcare Center, a 150-bed skilled ... effective January 1, 2009. The facility has been ... http://www.newscom.com/cgi-bin/prnh/20071213/LATH168LOGO )"This is a strategic acquisition, and ...
Cached Medicine News:Health News:Three Times More Powerful Than Fish Oil, MegaRed(TM) Omega-3 Krill Oil Now Available Nationwide 2Health News:Three Times More Powerful Than Fish Oil, MegaRed(TM) Omega-3 Krill Oil Now Available Nationwide 3Health News:Frost & Sullivan Awards Toshiba America Medical Systems for Innovation in Cardiovascular Imaging Products and Services 2Health News:Frost & Sullivan Awards Toshiba America Medical Systems for Innovation in Cardiovascular Imaging Products and Services 3Health News:Frost & Sullivan Awards Toshiba America Medical Systems for Innovation in Cardiovascular Imaging Products and Services 4Health News:Hard To Treat Diseases (HTDS) Completes E Europe Merger 2Health News:RBC Life Sciences Promotes Industry Veteran John W. Price to CEO; Company Founder, Clinton Howard, Will Remain Chairman of the Board 2Health News:RBC Life Sciences Promotes Industry Veteran John W. Price to CEO; Company Founder, Clinton Howard, Will Remain Chairman of the Board 3Health News:Alexion Pharmaceuticals and PDL BioPharma Resolve Patent Dispute 2Health News:Alexion Pharmaceuticals and PDL BioPharma Resolve Patent Dispute 3Health News:The Ensign Group Acquires Texas Skilled Nursing Facility 2
For the qualitative detection of single and multiple drugs and drug metabolites in human urine...
For the qualitative detection of single and multiple drugs and drug metabolites in human urine...
For the qualitative detection of single and multiple drugs and drug metabolites in human urine...
For the qualitative detection of cardiac troponin I (cTnl) in human whole blood and serum specimens...
Medicine Products: